文献综述(Review)

中晚期肝细胞肝癌的靶向治疗:困境与希望

Published at: 2017年第26卷第1期

郭之野 1 , 黄飞舟 1
1 中南大学湘雅三医院 普外一科,湖南 长沙410013
通讯作者 飞舟 黄 Email: huangfeizhou@medmail.com.cn
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2017.01.018
基金:

摘要

肝细胞肝癌(HCC)由于起病隐匿,大部分患者确诊时已失去根治的机会,故化学药物治疗在中晚期HCC治疗中有重要地位。随着在基因层面认识的提高和分子生物学研究的深入,对HCC的发病原因及分子通路都有了更新的了解,为靶向药物的运用提供了基础。近10余年来,HCC的靶向药物研究已取得部分成果,索拉非尼已被FDA批准用于治疗进展期HCC。然而其余靶向药物的临床试验结果却不尽人意,HCC靶向药物的研究似乎进入了瓶颈期。笔者就中晚期HCC的靶向药物治疗进展做一综述,并分析诸多临床试验失败的可能原因及可行的解决措施。


Targeted therapy for hepatocellular carcinoma of middle and advanced stage: quandaries and prospects

Abstract

Most patients with hepatocellular carcinoma (HCC) lose the opportunity for radical treatment due to the insidious onset of HCC, thus chemotherapy plays an important role in treatment of HCC at middle and advanced stage. The etiology for and the molecular pathways involved in HCC have been further understood with the development of genetic knowledge and molecular biology, which provide the biological rationale for targeted therapy. In more than 10 recent years, some advances have been achieved in targeted drugs for HCC, and sorafenib has already been approved by FDA for advanced HCC, while the results of other clinical trials of targeted drugs are less than satisfactory, and the research of targeted drugs for HCC seems to enter a stagnant state. Here, the authors discuss the current advances in targeted therapy for HCC and analyze the causes for the failure of many clinical trials as well as the potential solutions.


comments powered by Disqus

全文

引用

引用本文: 之野 郭, 飞舟 黄. 中晚期肝细胞肝癌的靶向治疗:困境与希望 [J]. 中国普通外科杂志, 2017, 26(1): 109-115.
Cite this article as: GUO Zhiye, HUANG Feizhou . Targeted therapy for hepatocellular carcinoma of middle and advanced stage: quandaries and prospects [J]. Chin J Gen Surg, 2017, 26(1): 109-115.